MHRA’s December 2025 defect notification for certain amitriptyline tablets says the patient information leaflet did not contain all required safety information and that the errors were identified following an MHRA Good Pharmacovigilance Practice inspection and further investigation by the marketing authorisation holder.
That is a valuable compliance lesson because it shows how PV findings do not always remain confined to case handling or database processes. They can surface in product information, patient communication, and other areas where missing safety content directly affects risk communication.
For inspection-readiness thinking, this is a reminder that pharmacovigilance quality is not only about submitting reports on time. It is also about whether safety knowledge is being correctly reflected in the materials that guide real-world use.
0 Comments